~~U.S.~~UNITED ~~SECURITIES AND EXCHANGE COMMISSION~~STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Mark One

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the ~~quarterly~~Quarterly ~~period~~Period ~~ended~~Ended ~~May~~November 3130, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ~~______~~_________ to ~~_______~~_________

~~COMMISSION~~Commission ~~FILE~~File ~~NO.~~Number 333-234137

~~AZAR~~QLY ~~INTERNATIONAL~~BIOTECH GROUP CORP. (Exact name of registrant issuer as specified in its charter)

Nevada	7999	98-1448750
(State or Other Jurisdiction ofIncorporation or Organization)	(Primary Standard IndustrialClassification Number)	(IRS EmployerIdentification Number)
(State or Other jurisdiction ofincorporation or organization)	(Primary Standard IndustrialClassification Number)	(I.R.S. EmployerIdentification No.)

~~Azar~~5348 ~~International~~VEGAS ~~Corp.~~ DRIVE, LAS VEGAS, Nevada 89108

~~Carretera~~(Address ~~Turistica,~~of ~~Luperon,~~principal ~~12th~~executive kmoffices, ~~No.~~including 7zip code)

~~Grand~~(+86) ~~Parada, Puerto Plata, Dominican Republic~~18678961296

~~(829)~~Registrant’s ~~947-5251~~phone number, including area code

~~(Address~~Securities ~~and~~registered ~~telephone~~pursuant ~~number~~to Section 12(b) of ~~registrant’s~~the ~~executive~~Act: ~~office)~~ None

~~Indicate~~Securities byregistered ~~checkmark~~pursuant ~~whether the issuer: (1) has filed all reports required~~ to ~~be filed by~~ Section ~~13 or 15~~12(dg) of the ~~Exchange~~ Act ~~during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes~~: ~~☒ No ☐~~

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Title of each class

Trading Symbol(s)

Name of each exchange

on which registered

Common stock, $.001 par value

LQLY

N/A

Indicate by check mark ~~whether~~if the registrant is a ~~large~~well-known ~~accelerated~~seasoned ~~filed~~issuer, anas ~~accelerated~~defined ~~filer,~~in aRule ~~non-accelerated~~405 ~~filer,~~of orthe aSecurities ~~smaller reporting company~~Act.

~~Large~~Yes ~~accelerated filer~~ ☐ No ~~Accelerated filer ☐ Non-accelerated Filer ☐ Smaller reporting company~~ ☒ ~~Emerging growth company ☒~~

IfIndicate ~~an emerging growth company, indicate~~ by check mark if the registrant ~~has~~is ~~elected~~ not required to ~~use~~file ~~the~~reports ~~extended~~pursuant ~~transition~~to ~~period~~Section ~~for~~13 ~~complying with any new~~ or ~~revised financial accounting standards provided pursuant to~~ Section 1315(ad) of the ~~Exchange~~ Act. ~~YES ☐ NO ☒~~

~~Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).~~ Yes ☒ ☐ No ☐☒

~~Applicable~~Indicate ~~Only~~by check mark whether the registrant (1) has filed all reports required to ~~Issuer~~be ~~Involved~~filed inby ~~Bankruptcy~~Section ~~Proceedings~~13 ~~During~~or 15(d) of the ~~Preceding~~Securities ~~Five~~Exchange ~~Years.~~Act ~~N/A~~of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Indicate by checkmark whether the issuer has filed all documents and reports required to be filed by Section 12, 13 and 15(d) of the Securities Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes ~~☐ No~~☒ NO ☐

~~Applicable~~Indicate ~~Only~~by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to ~~Corporate~~be ~~Registrants~~submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

~~Indicate~~Yes ☒ NO ~~the number of shares outstanding of each of the issuer’s classes of common stock, as of the most practicable date:~~☐

Class	Outstanding as of June 10, 2022
Common Stock, $0.001	3,895,000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” or an “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

~~AZAR~~Large ~~INTERNATIONAL~~accelerated ~~CORP.~~filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒

Part I	Financial information
Item 1	Financial statements (unaudited)	3
Item 2	Management’s discussion and analysis of financial condition and results of operations	11
Item 3	Quantitative and qualitative disclosures about market risk	13
Item 4	Controls and procedures	13
PART II	Other Information
Item 1	Legal proceedings	14
Item 2	Unregistered sales of equity securities and use of proceeds	14
Item 3	Defaults upon senior securities	14
Item 4	Mine safety disclosures	14
Item 5	Other information	14
Item 6	Exhibits	14
	Signatures	15

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

2Indicate ~~Table~~by check mark whether the registrant has filed a report on and attestation to its management’s assessment of ~~Contents~~the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

~~AZAR~~Indicate ~~INTERNATIONAL~~by ~~CORP~~check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

~~BALANCE~~Yes ~~SHEETS~~☐ No ☒

	MAY 31, 2022(Unaudited)			AUGUST 31, 2021(Audited)
ASSETS
Current Assets
Cash & cash equivalents	$	668		$	5,169
Prepaid expenses		500			-
Total current assets	$	1,168		$	5,169
Non-Current assets
Equipment (net)		40			123
Intangible assets (net)		667			1,867
Total non-Current assets	$	707			1,990
TOTAL ASSETS	$	1,875		$	7,159
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Loans from related parties	$	17,107		$	11,597
Accounts Payable		3			1,525
Total current liabilities		17,110			13,122
Total Liabilities	$	17,110		$	13,122
Stockholders’ Equity (Deficit)
Common stock, $0.001 par value, 75,000,000 shares authorized; 3,895,000 shares issued and outstanding		3,895			3,895
Additional Paid-In-Capital		25,955			25,955
Accumulated Deficit		(45,085	)		(35,813	)
Total Stockholders’ equity (deficit)	$	(15,235	)	$	(5,963	)
Total Liabilities and Stockholders’ Equity (Deficit)	$	1,875		$	7,159

The aggregate market value of the voting stock and non-voting common equity held by non-affiliates of the registrant as of January 13, 2023, was approximately $0.9 million.

~~The~~Indicate ~~accompanying~~the ~~notes~~number ~~are~~of anshares ~~integral~~outstanding ~~part~~of each of ~~these~~the ~~financial~~issuer’s ~~statements~~classes of common stock, as of the latest practicable date.

3 Table of Contents

Class		Outstanding at January 13, 2023
Common Stock, $.001 par value		3,895,000

~~AZAR~~TABLE ~~INTERNATIONAL~~OF ~~CORP.~~CONTENTS

STATEMENTS OF OPERATIONS

		Page

PART I	FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS:	F-1
	Condensed Balance Sheets as of November 30, 2022 and August 31, 2022 (unaudited)	F-1
	Condensed Statements of Operations and Comprehensive Loss for the three months ended November 30, 2022 and 2021 (unaudited)	F-2
	Condensed Statement of Changes in Stockholders’ Deficit for the three months ended November 30, 2022 and 2021 (unaudited)	F-3
	Condensed Statements of Cash Flows for the three months ended November 30, 2022 and 2021(unaudited)	F-4
	Notes to the Condensed Financial Statements (unaudited)	F-5
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	2
ITEM 3.	QUANTITATIVE AND QUALITATIVED IS CLOSURES ABOUT MARKET RISK	4
ITEM 4.	CONTROLS AND PROCEDURES	4

PART II	OTHER INFORMATION

ITEM 1	LEGAL PROCEEDINGS	5
ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	5
ITEM 3	DEFAULTS UPON SENIOR SECURITIES	5
ITEM 4	MINE SAFETY DISCLOSURES	5
ITEM 5	OTHER INFORMATION	5
ITEM 6	EXHIBITS	6
	SIGNATURES	7

~~(UNAUDITED)~~1 Table of Contents

	Three months ended May 31, 2022			Three months ended May 31, 2021			Nine months ended May 31, 2022			Nine months ended May 31, 2021
Revenue	$	-		$	-		$	-		$	-
OPERATING EXPENSES
Cost of sales		-			-			-			-
General and administrative expenses		3,305			1,790			9,272			30,100
Total Operation expenses		3,305			1,790			9,272			30,100
Income (Loss) before provision for income taxes		(3,305	)		(1,790	)		(9,272	)		(30,100	)
Provision for income taxes
Net income (loss)	$	(3,305	)	$	(1,790	)	$	(9,272	)	$	(30,100	)
Income (loss) per common share:
Basic and Diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
Weighted Average Number of Common Shares Outstanding:
Basic and Diluted		3,895,000			3,895,000			3,895,000			3,895,000

PART I – FINANCIAL INFORMATION

~~The~~Item ~~accompanying~~1. ~~notes~~Financial ~~are an integral part of these financial~~ statements.

4QLY ~~Table~~BIOTECH ofGROUP ~~Contents~~CORP.

~~AZAR~~CONDENSED ~~INTERNATIONAL~~BALANCE ~~CORP.~~SHEETS

~~STATEMENT~~AS OF ~~STOCKHOLDER’S~~NOVEMBER ~~EQUITY~~30, 2022 AND AUGUST 31, 2022 (~~DEFICIT~~Unaudited)

~~FOR~~(Currency ~~THE~~expressed ~~NINE~~in ~~MONTHS~~United ~~PERIODS~~States ~~ENDED~~Dollars ~~MAY 31~~(“US$”), ~~2022~~except ~~AND~~for ~~2021~~number of shares)

(UNAUDITED)

	As of
	November 30, 2022			August 31, 2022
ASSETS
TOTAL ASSETS	$	-		$	-

LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accrued liabilities	$	3,500		$	-
Amount due to a director		4,548			-
Total current liabilities		8,048			-

TOTAL LIABILITIES	$	8,048		$	-

STOCKHOLDERS’ DEFICIT
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 3,895,000 shares issued and outstanding as of November 30, 2022 and August 31, 2022, respectively	$	3,895		$	3,895
Additional paid-in capital		47,150			46,030
Accumulated deficit		(59,093	)		(49,925	)
TOTAL STOCKHOLDERS’ DEFICIT		(8,048	)		-

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	-		$	-

	Number ofCommonShares		Amount		Additional Paid-In-Capital		Deficitaccumulated			Total
Balance at August 31, 2020		3,895,000	$	3,895	$	25,955	$	(6,310	)	$	23,540
Net loss		-		-		-		(4,541	)		(4,541	)
Balances as of November 30, 2020		3,895,000	$	3,895	$	25,955	$	(10,851	)	$	18,999
Net loss		-		-		-		(23,769	)		(23,769	)
Balances as of February 28, 2021		3,895,000	$	3,895	$	25,955	$	(34,620	)	$	(4,770	)
Net loss		-		-		-		(1,790	)		(1,790	)
Balances as of May 31, 2021		3,895,000	$	3,895	$	25,955	$	(36,410	)	$	(6,560	)
Balances as of August 31, 2021		3,895,000	$	3,895	$	25,955	$	(35,813	)	$	(5,963	)
Net loss		-		-		-		(4,212	)		(4,212	)
Balances as of November 30, 2021		3,895,000	$	3,895	$	25,955	$	(40,025	)	$	(10,175	)
Net loss		-		-		-		(1,755	)		(1,755	)
Balances as of February 28, 2022		3,895,000	$	3,895	$	25,955	$	(41,780	)	$	(11,930	)
Net loss		-		-		-		(3,305	)		(3,305	)
Balances as of May 31, 2022		3,895,000	$	3,895	$	25,955	$	(45,085	)	$	(15,235	)

See accompanying notes to the unaudited condensed financial statements.

~~The~~F-1 ~~accompanying~~Table ~~notes are an integral part~~ of ~~these financial statements.~~Contents

5QLY ~~Table~~BIOTECH ofGROUP ~~Contents~~CORP.

~~AZAR~~CONDENSED ~~INTERNATIONAL~~STATEMENTS ~~CORP.~~OF OPERATIONS AND COMPREHENSIVE LOSS

~~STATEMENTS~~FOR OFTHE ~~CASH~~THREE ~~FLOWS~~MONTHS ENDED NOVEMBER 30, 2022 AND 2021 (Unaudited)

(~~UNAUDITED~~Currency expressed in United States Dollars (“US$”), except for number of shares)

	Nine months ended May 31, 2022			Nine months ended May 31, 2021
	For three months ended November 30,
CASH FLOWS FROM OPERATING ACTIVITIES
	2022			2021
Net loss	$	(9,272	)	$	(30,100	)
REVENUES	$	-		$	-
Accounts Payable		(1,522	)		10,000
COSTS OF REVENUES		-			-
Prepaid Expenses		(500	)		-
GROSS INCOME		-			-
Adjustments as of non-cash items
GENERAL & ADMINISTRATIVE EXPENSES		9,168			4,212
Depreciation		83			84
LOSS BEFORE INCOME TAX		(9,168	)		(4,212	)
Amortization		1,200		1200
INCOME TAX EXPENSES		-			-
Net cash provided by (used in) Operating activities		(10,011	)		(18,816	)
NET LOSS	$	(9,168	)	$	(4,212	)
CASH FLOWS FROM FINANCING ACTIVITIES
Other comprehensive gain (loss):
Proceeds from sale of common stock		-			-
Foreign exchange adjustment gain (loss)		-			-
Proceeds of loan from shareholder		5,510			3,800
COMPREHENSIVE LOSS	$	(9,168	)	$	(4,212	)
Net cash provided by Financing activities		5,510			3,800
Net loss per share - Basic and diluted	$	(0.00	)	$	(0.00	)
Increase (decrease) in cash and equivalents		(4,501	)		(15,016	)
Weighted average number of common shares outstanding – Basic and diluted		3,895,000			3,895,000
Cash and equivalents at beginning of the period		5,169			27,634
Cash and equivalents at end of the period	$	668		$	12,618
Supplemental cash flow information:
Cash paid for:
Interest	$	-		$	-
Taxes	$	-		$	-

~~The~~See accompanying notes ~~are~~to anthe ~~integral~~unaudited ~~part~~condensed ~~of these~~ financial statements.

6F-2 Table of Contents

~~AZAR~~QLY ~~INTERNATIONAL~~BIOTECH GROUP CORP.

~~NOTES~~CONDENSED TOSTATEMENTS ~~THE~~OF ~~AUDITED~~CHANGES ~~FINANCIAL~~IN ~~STATEMENTS~~STOCKHOLDERS’ DEFICIT

FOR THE ~~NINE~~THREE MONTHS ~~PERIOD~~ ENDED ~~MAY~~NOVEMBER 3130, 2022 AND 2021 (Unaudited)

~~NOTE~~(Currency ~~1 –~~expressed ~~ORGANIZATION~~in ~~AND~~United ~~BUSINESS~~States Dollars (“US$”), except for number of shares)

~~AZAR~~For ~~INTERNATIONAL CORP. (~~the ~~“Company”)~~three ismonths aended ~~corporation~~November ~~established under the corporation laws in the State of Nevada on September 20~~30, ~~2018. Azar International Corp. is in the tourism business.~~2022

The Company has adopted August 31 fiscal year end.

	COMMON STOCK					ADDITIONAL				TOTAL
	Number of shares		Amount		PAID-IN CAPITAL		ACCUMULATED DEFICIT				STOCKHOLDER DEFICT
Balance as of September 1, 2022		3,895,000	$	3,895	$	46,030	$	(49,925	)		$	-
Satisfaction of amount due to current shareholder on November 30, 2022		-		-		1,120		-				1,120
Net loss		-		-		-		(9,168	)			(9,168	)
Balance as of November 30, 2022		3,895,000	$	3,895	$	47,150	$	(59,093	)		$	(8,048	)

~~NOTE~~For ~~2 –~~the ~~GOING~~three ~~CONCERN~~months ended November 30, 2021

The Company’s financial statements as of May 31, 2022 have been prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The Company has accumulated loss from inception (September 20, 2018) to May 31, 2022 of $45,085. These factors among others raise substantial doubt about the ability of the company to continue as a going concern for a reasonable period of time.

	COMMON STOCK				ADDITIONAL					TOTAL
	Number of shares		Amount		PAID-IN CAPITAL		ACCUMULATED DEFICIT			STOCKHOLDER DEFICT
Balance as of September 1, 2021		3,895,000	$	3,895	$	25,955	$	(35,813	)	$	(5,963	)
Net loss		-		-		-		(4,212	)		(4,212	)
Balance as of November 30, 2021		3,895,000	$	3,895	$	25,955	$	(40,025	)	$	(10,175	)

~~During~~See ~~the~~accompanying ~~quarter~~notes ~~ended~~to ~~May 31, 2022,~~ the ~~Company~~unaudited ~~was~~condensed ~~negatively~~financial ~~impacted by the effects of the worldwide COVID-19 pandemic~~statements. ~~The Company’s business is tourism in the Dominican Republic. Border closer, travel bans and quarantine place doubt on the Company’s revenue, which could result in continued losses.~~

InF-3 ~~order~~Table to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plan is to obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its minimal operating expenses and seeking third party equity and/or debt financing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.Contents

~~NOTE~~QLY ~~3 –~~BIOTECH ~~SUMMARY~~GROUP ~~OF SIGNIFICANT ACCOUNTING POLICIES~~CORP.

~~Basis~~CONDENSED ofSTATEMENTS ~~Presentation~~OF CASH FLOWS

~~The~~FOR ~~financial~~THE ~~statements~~THREE ofMONTHS ~~the~~ENDED ~~Company~~NOVEMBER ~~have been prepared in accordance with generally accepted accounting principles in the United States of America. The results for the nine months ended May 31~~30, 2022 ~~are~~AND not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10K for the year ended August 31, 2021, ~~filed with the Securities and Exchange Commission.~~(Unaudited)

~~The~~(Currency ~~accompanying~~expressed ~~condensed~~in ~~financial~~United ~~statements~~States ~~have~~Dollars ~~been prepared by the Company without audit. In the opinion of management, all adjustments~~ (~~which include only normal recurring adjustments~~“US$”) ~~necessary to present fairly the financial position~~, ~~results~~except ~~of operations, and cash flows at May 31, 2022 and~~ for ~~the~~number ~~related~~of ~~periods presented.~~shares)

New Accounting Pronouncements

	For the three months ended November 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(9,168	)	$	(4,212	)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization cost and depreciation		-			428

Changes in operating assets and liabilities:
Accounts payable		-			(1,025	)
Accrued liabilities		3,500			-
Net cash used in operating activities		(5,668	)		(4,809	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds of loan from former shareholder		-			800
Proceeds of loan from current shareholder		5,668			-
Net cash generated from financing activities		5,668			800

Effect of exchange rate changes on cash and cash equivalents		-			-

Net change in cash and cash equivalents		-			(4,009	)
Cash and cash equivalents, beginning of year		-			5,169

CASH AND CASH EQUIVALENTS, END OF YEAR	$	-		$	1,160

SUPPLEMENTAL CASH FLOWS INFORMATION
Income taxes paid	$	-		$	-
Interest paid	$	-		$	-

NON-CASH INVESTMENT AND FINANCING ACTIVITIES
Satisfaction of amount due to current shareholder on November 30, 2022	$	1,120		$	-

~~There~~See ~~were~~accompanying ~~various~~notes ~~accounting standards and interpretations issued recently, none of which are expected~~ to athe ~~have~~unaudited acondensed ~~material impact on our~~ financial ~~position, operations or cash flows~~statements.

7F-4 Table of Contents

~~Cash~~QLY ~~and~~BIOTECH ~~Cash~~GROUP ~~Equivalents~~CORP.

~~For~~NOTES ~~purposes~~TO ofCONDENSED ~~the~~FINANCIAL statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company’s bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At May 31, 2022, the Company’s bank deposits did not exceed the insured amounts.STATEMENTS

~~Stock-Based~~FOR ~~Compensation~~THE THREE MONTHS ENDED NOVEMBER 30, 2022 (Unaudited)

As(Currency ofexpressed ~~May~~in ~~31,~~United ~~2022,~~States ~~the~~Dollars ~~Company~~(“US$”), ~~has~~except ~~not~~for ~~issued~~number ~~any~~of ~~stock-based payments to its employees.~~shares)

~~Stock-based~~NOTE ~~compensation~~1 is– ~~accounted~~ORGANIZATION ~~for~~AND atBUSINESS ~~fair value in accordance with ASC 718, when applicable. To date, the Company has not adopted a stock option plan and has not granted any stock options.~~BACKGROUND

~~Use~~QLY Biotech Group Corp., a Nevada corporation (“the Company” or “QLY”) was incorporated under the laws of ~~Estimates~~the ~~and~~State ~~Assumptions~~of Nevada on September 20, 2018.

The ~~preparation~~Company ofwas ~~financial~~used ~~statements~~to engaged in ~~conformity~~the ~~with~~tourism. ~~generally~~The ~~accepted~~company ~~accounting~~used ~~principles requires management~~ to ~~make~~organize ~~estimates~~individual and ~~assumptions~~group ~~that~~sailing ~~affect~~tours in the ~~reported~~Dominican ~~amounts~~Republic. ofServices ~~assets~~ and ~~liabilities~~itineraries ~~and~~were ~~disclosure~~used ofto ~~contingent~~be ~~assets~~provide ~~and~~by ~~liabilities~~our atcompany ~~the~~include ~~date~~custom ofpackages ~~the~~according ~~financial~~to ~~statements~~the ~~and~~client’s ~~the~~specifications. ~~reported~~And ~~amounts~~we ofused ~~revenues~~to develop and ~~expenses~~offer ~~during~~our own sailing tours in the ~~period.~~North ~~Actual~~part ~~results~~of ~~could~~Dominican ~~differ~~Republic ~~from~~as ~~those~~well ~~estimates~~as third-party suppliers.

~~Due~~On July 8, 2022, as a result of a private transactions, 3,000,000 shares of common stock, $0.001 par value per share (the “Shares”) of QLY Biotech Group Corp. (Former name: Azar International Corp.)., were transferred from Hilario Lopez Vargas to Lixue Yang. As a result, Lixue Yang became holders of approximately 77% of the ~~limited~~voting ~~level~~rights of ~~operations~~the issued and outstanding share capital of the Company and became the controlling shareholder. The consideration paid for the Shares was $350,000. The source of the cash consideration for the Shares was personal funds of Lixue Yang. In connection with the transaction, Hilario Lopez Vargas released the Company ~~has~~from ~~not~~all ~~had~~debts owed to ~~make~~him, ~~material~~and ~~assumptions~~the orCompany ~~estimates~~agreed ~~other~~to ~~than~~assign the ~~assumption~~Computer and Designer (that were acquired by the Company ison aSeptember ~~going~~30, ~~concern~~2019 and November 1, 2019, respectively) to him.

~~Fair~~On ~~Value~~July 8, 2022, the existing director and officer resigned immediately. Accordingly, Hilario Lopez Vargas, serving as a director and an officer, ceased to be the Company’s Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and a Director. At the effective date of the transfer, Lixue Yang consented to act as the new Chief Executive Officer, Chief Financial ~~Instruments~~Officer, President, Treasurer, Secretary and a Director of the Company.

~~ASC~~NOTE ~~825,~~2 ~~“Disclosures~~- ~~about~~GOING ~~Fair~~CONCERN Value of Financial Instruments”, requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022.UNCERTAINTIES

~~The~~As ~~respective~~of ~~carrying~~November ~~values~~30, 2022, the Company suffered an accumulated deficit of ~~certain~~$59,093 ~~on-balance-sheet~~and ~~financial~~incurred ~~instruments~~a ~~approximate~~net ~~their~~loss ~~fair~~of ~~values~~$9,168. ~~These~~The ~~financial~~continuation ~~instruments~~of ~~include~~the ~~cash,~~Company ~~accounts~~as ~~payable~~a ~~and~~going ~~related~~concern ~~party~~through ~~loan~~November ~~payable.~~30, ~~Fair~~2022 ~~values~~is ~~were~~dependent ~~assumed~~upon toimproving ~~approximate~~the ~~carrying~~profitability ~~values~~and ~~for~~the ~~these~~continuing financial ~~instruments~~support ~~since~~from ~~they~~its ~~are~~stockholders. ~~short~~Management ~~term~~believes inthe ~~nature~~existing ~~and~~shareholders ~~their~~or ~~carrying~~external ~~amounts~~financing ~~approximate~~will ~~fair~~provide ~~value~~the additional cash to meet the Company’s obligations as they become due.

~~Income~~These ~~Taxes~~and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result in the Company not being able to continue as a going concern.

~~Income~~NOTE ~~taxes~~3 ~~are~~- ~~provided~~SUMMARY inOF ~~accordance~~SIGNIFICANT ~~with~~ACCOUNTING ASC No. 740, Accounting for Income Taxes. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carry forwards. Deferred tax expense (benefit) results from the net change during the year of deferred tax assets and liabilities.POLICIES

~~Deferred~~The ~~tax~~accompanying ~~assets~~unaudited ~~are~~condensed ~~reduced~~financial bystatements areflect ~~valuation allowance when, in~~ the ~~opinion~~application of ~~management,~~certain itsignificant isaccounting ~~more~~policies ~~likely~~as ~~than~~described ~~not~~in ~~that~~this ~~some~~note ~~portion of all of the deferred tax assets will be realized. Deferred tax assets~~ and ~~liabilities~~elsewhere ~~are~~in ~~adjusted for~~ the ~~effects~~accompanying offinancial ~~changes~~statements ~~in tax laws~~ and ~~rates on the date of enactment~~notes.

8● ~~Table~~Basis of ~~Contents~~presentation

~~Revenue~~The ~~Recognition~~financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America. The Company’s fiscal year end is August 31. The Company’s financial statements are presented in U.S. dollars.

We● ~~adopted~~Use ~~Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers”, and all related interpretations for recognition~~ of ~~our revenue from tours and services. Previously we recorded revenue based on ASC Topic 605. Adoption of new accounting standard did not have any material impact on our reported revenue.~~estimates

~~Revenue~~In ispreparing ~~recognized~~these ~~when~~condensed financial statements, management makes estimates and assumptions that affect the ~~following~~reported ~~criteria~~amounts ~~are~~of ~~met:~~assets and liabilities in the balance sheets and revenues and expenses during the periods reported. Actual results may differ from these estimates.

·● ~~Identification~~Cash of the contract, or contracts, with customer; · Identification of the performance obligations in the contract; · Determination of the transaction price; · Allocation of the transaction price to the performance obligations in the contract; and ·cash ~~Recognition of revenue when, or as, we satisfy performance obligation.~~equivalents

The ~~Company~~company ~~has~~considers ~~evaluated~~ all ~~the~~highly ~~recent~~liquid ~~accounting~~instruments ~~pronouncements~~with ~~and~~a ~~determined~~maturity ~~that~~of ~~there~~three ~~are~~months noor ~~other~~less ~~accounting~~at ~~pronouncements~~the ~~that~~time ~~will~~of ~~have~~issuance ato ~~material~~be ~~effect~~cash ~~on the Company’s financial statements~~equivalents.

~~Fixed~~F-5 ~~Assets~~Table of Contents

~~Fixed~~QLY ~~assets~~BIOTECH ~~are~~GROUP ~~stated at cost, net of accumulated depreciation and accumulated impairment losses, if any~~CORP. The cost comprises purchase price, borrowing costs, if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any subsidy/reimbursement/contribution received for installation and acquisition of any fixed assets is shown as deduction in the year of receipt. Capital work- in progress is stated at cost.

~~Subsequent~~NOTES ~~expenditure~~TO ~~related~~CONDENSED toFINANCIAL an item of fixed assets is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing fixed assets, including day-to-day repairs and maintenance expenditure and cost of replacing parts, are charged to the Statement of Profit and Loss for the period during which such expenses are incurred.STATEMENTS

~~Gains~~FOR orTHE ~~losses~~THREE ~~arising~~MONTHS ~~from~~ENDED ~~de-recognition~~NOVEMBER of30, ~~fixed~~2022 ~~assets are measured as the difference between the net disposal proceeds and the carrying amount of the assets derecognized.~~(Unaudited)

~~The~~(Currency ~~Company~~expressed ~~utilizes~~in ~~straight-line~~United ~~depreciation~~States ~~over~~Dollars ~~the~~(“US$”), ~~estimated~~except ~~useful~~for ~~life~~number of ~~the asset.~~shares)

~~Office~~● ~~Equipment~~Property, –plant 3and ~~years~~equipment

~~Earnings~~Property, ~~per~~plant ~~Share~~and equipment are carried at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line method. Estimated useful lives of the property and equipment are as follows:

~~ASC~~Office ~~No.~~equipment ~~260,~~3 “Earnings Per Share”, specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. The Company has adopted the provisions of ASC No. 260.years

~~Basic~~The ~~net~~cost ~~loss~~of ~~per~~maintenance ~~share~~and ~~amounts~~repairs is ~~computed~~charged byto ~~dividing~~expenses ~~the~~as ~~net~~incurred, ~~loss~~whereas bysignificant ~~the~~renewals ~~weighted~~and ~~average~~betterments ~~number of common shares outstanding. Diluted earnings per share~~ are ~~the same as basic earnings per share due to the lack of dilutive items in the Company~~capitalized.

~~Risks~~● ~~and~~Intangible ~~Uncertainties~~assets, net

InIntangible ~~December~~assets ~~2019,~~with adefinite ~~novel~~lives ~~strain~~are ofstated ~~coronavirus~~at ~~surfaced~~cost inless ~~China,~~accumulated ~~which has and is continuing to spread throughout the world, including the United States and Dominican Republic~~amortization. On January 30, 2020, the World Health Organization declared the outbreak of the coronavirus disease (COVID-19) a “Public Health Emergency of International Concern,” and on March 11, 2020, the World Health Organization characterized the outbreak as a “pandemic”. The governors of New York, California and several other states, as well as mayors on many cities, have ordered their residents to cease traveling to non-essential jobs and to curtail all unnecessary travel, and to stay in their homes as much as possible in the coming weeks, as the nation confronts the escalating coronavirus outbreak, and similar restrictions have been recommended by the federal authorities and authorities in many other states and cities. The Company is not able to predict the ultimate impact that COVID -19 will have on its business; however, if the current economic conditions continue, the Company will be forced to significantly scale back its business operations and its growth plans, and could ultimately have a significant negative impact on the Company.

9Amortization ~~Table~~is ofcalculated ~~Contents~~on the straight-line basis over the following estimated useful lives:

~~NOTE~~Website 43 ~~– EQUIPMENT (NET)~~years

~~Company~~● ~~purchased~~Revenue ~~equipment as on September 30, 2019 for $339.~~ recognition

The Company ~~depreciates~~assesses ~~its~~and ~~property~~follows ~~using~~the ~~straight-line~~guidance ~~depreciation~~of ~~over~~ASC ~~the~~606, ~~estimated~~revenue ~~useful~~from ~~life~~contracts ofwith 3customers ~~years.~~is recognized using the following five steps:

~~For~~1. Identify the ~~nine-month~~contract(s) ~~period~~with ~~ended~~a ~~May~~customer; ~~31,~~2. ~~2022~~Identify the ~~company~~performance ~~recorded~~obligations ~~$83~~ in ~~depreciation~~the ~~expense~~contract; 3. ~~From~~Determine ~~inception~~the ~~(September~~transaction ~~20,~~price; ~~2018)~~4. ~~through~~Allocate ~~May~~the ~~31,~~transaction ~~2022~~price to the ~~company~~performance ~~has~~obligations ~~recorded~~in athe ~~total~~contract; ofand ~~$299~~5. inRecognize ~~depreciation~~revenue ~~expense~~when (or as) the entity satisfies a performance obligation.

~~NOTE~~The 5Company –had ~~INTANGIBLE~~generated ~~ASSETS~~zero revenue during the three months ended November 30, 2022 and 2021, respectively.

~~Intangibles~~● ~~comprise~~Income ~~of Company’ website. The website was purchased on October 31, 2019 for $4,800. The Company amortize its intangible using straight-line depreciation over the estimated useful life of 3 years.~~taxes

~~For~~The Company followed the ~~nine-month~~liability ~~period~~method ~~ended~~of ~~May~~accounting 31for income taxes in accordance with ASC 740, ~~2022~~Income ~~the~~Taxes, ~~company~~or ~~recorded~~ASC $1740. Under this method,~~200~~ deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in ~~amortization~~effect ~~expense~~in the period in which the differences are expected to reverse. ~~From~~The ~~inception~~Company ~~(September~~recorded 20a valuation allowance to offset deferred tax assets if based on the weight of available evidence, ~~2018)~~it ~~through~~is ~~May~~more-likely-than-not 31that some portion, ~~2022~~or all, of the ~~company~~deferred ~~has~~tax ~~recorded~~assets awill ~~total~~not be realized. The effect on deferred taxes of ~~$4,133~~a change in ~~amortization~~tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.

~~NOTE~~The 6Company –accounted ~~CAPITAL~~for ~~STOCK~~uncertainties in income taxes in accordance with ASC 740. Interest and penalties related to unrecognizable tax benefit recognized in accordance with ASC 740 are classified in the statements of comprehensive loss as income tax expense.

~~The~~● ~~Company~~Earnings ~~has 75,000,000 shares of common stock authorized with a par value of $0.001~~ per share.

InThe ~~November~~Company ~~2018~~computes earnings per share (“EPS”) in accordance with ASC Topic 260, “Earnings per share”. Basic EPS is measured as the ~~Company~~income ~~issued~~or ~~3,000,000~~loss available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of ~~its~~potential common ~~stock~~shares (e.g., convertible securities, options, and warrants) as if they had been converted at $0the beginning of the periods presented, or issuance date, if later.~~001~~ Any potential common shares in 2022 and 2021 that have an anti-dilutive effect (i.e. those that increase income per share ~~for~~or ~~total~~decrease ~~proceeds~~loss per share) are excluded from the calculation of ~~$3,000~~diluted EPS.

InF-6 ~~July~~Table ~~and August 2020, the Company issued 895,000 shares~~ of ~~its common stock at $0.03 per share for total proceeds of $26,850.~~Contents

AsQLY ofBIOTECH ~~May~~GROUP ~~31, 2022, the Company had 3,895,000 shares issued and outstanding~~CORP.

~~NOTE~~NOTES 7TO –CONDENSED ~~RELATED~~FINANCIAL ~~PARTY TRANSACTIONS~~STATEMENTS

InFOR ~~support~~THE ofTHREE ~~the~~MONTHS ~~Company’s~~ENDED ~~efforts~~NOVEMBER ~~and cash requirements~~30, it2022 may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by officers, directors, or shareholders. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances are considered temporary in nature and have not been formalized by a promissory note. (Unaudited)

~~Since September 20, 2018~~ (~~Inception)~~Currency ~~through~~expressed ~~May~~in ~~31,~~United ~~2022,~~States ~~the~~Dollars ~~Company’s sole officer and director loaned the Company~~ (“US$17”),~~107~~ toexcept ~~pay~~ for ~~incorporation~~number ~~costs and operating expenses. As~~ of ~~May 31, 2022, the amount outstanding was $17,107. The loan is non-interest bearing, due upon demand and unsecured.~~shares)

~~NOTE~~● 8.Related ~~SUBSEQUENT~~party ~~EVENTS~~transaction

~~The~~A ~~Company~~related ~~has~~party ~~evaluated~~is ~~subsequent~~generally ~~events~~defined ~~from~~as ~~May~~(i) 31any person that holds 10% or more of the Company’s securities and their immediate families, ~~2022~~(ii) tothe ~~June~~Company’s 9management, ~~2022~~(iii) someone that directly or indirectly controls, is controlled by or is under common control with the ~~date~~Company, or (iv) anyone who can significantly influence the financial ~~statements~~and ~~were~~operating ~~issued~~decisions ~~and~~of ~~has~~the ~~determined~~Company. ~~that~~A transaction is considered to be a related party transaction when there ~~are~~is noa ~~items~~transfer toof ~~disclose~~resources or obligations between related parties.

10Transactions ~~Table~~involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of ~~Contents~~competitive, free market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.

~~ITEM~~● 2.Recent ~~MANAGEMENT’S~~accounting ~~DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION~~pronouncements

~~FORWARD~~The ~~LOOKING~~Company ~~STATEMENTS~~has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

~~Statements~~NOTE ~~made~~4 in– ~~this~~ACCRUED Form 10-Q that are not historical or current facts are “forward-looking statements” made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 (the “Act”) and Section 21E of the Securities Exchange Act of 1934. These statements often can be identified by the use of terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “approximate” or “continue,” or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management’s best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.LIABILITIES

~~DESCRIPTION~~As OFof ~~BUSINESS~~November 30, 2022, the balance of accrued liabilities was $3,500 that including the audit fee and stock agency expenses. As of August 31, 2022, the balance of accrued liabilities was $0.

OnNOTE ~~September~~5 ~~20,~~- ~~2018,~~AMOUNT ~~the~~DUE ~~Company~~TO ~~was~~A incorporated under the laws of the State of Nevada. We are engaged in the tourism. Azar International Corp. organizes individual and group sailing tours in the Dominican Republic. Services and itineraries provided by our company include custom packages according to the client’s specifications. We develop and offer our own sailing tours in the North part of Dominican Republic as well as third-party suppliers.DIRECTOR

~~RESULTS~~As OFof ~~OPERATIONS~~November 30, 2022 and August 31, 2022, the director of the Company, Mr. Lixue Yang, advanced $4,548 and $0 to the Company, respectively, which is unsecured, interest-free with no fixed payment term, for working capital purpose.

~~Our~~NOTE ~~financial~~6 ~~statements~~– ~~have~~COMMON been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.STOCK

WeAs ~~expect~~of weNovember ~~will~~30, ~~require~~2022 ~~additional~~and ~~capital~~August to31, ~~meet~~2022, ~~our~~the ~~long-term~~Company ~~operating~~has 1,000,000,000 share ~~requirements.~~authorized, 3,895,000 shares Weissued ~~expect~~and ~~to raise additional capital through~~outstanding, ~~among~~respectively. ~~other~~There ~~things,~~are ~~the~~no ~~sale~~shares of ~~equity~~preferred orstock ~~debt~~issued ~~securities~~and outstanding.

AsNOTE ~~of May 31, 2022, our total assets were $1,875 compared to $~~7~~,159~~ in– ~~total~~ADDITIONAL ~~assets~~PAID-IN atCAPITAL ~~August~~– ~~31,~~CAPITAL ~~2021. As of May 31, 2022, our total liabilities were $17,110 compared to $13,122 in total liabilities at August 31, 2021.~~CONTRIBUTION

~~Stockholders’~~As ~~deficit~~of ~~was~~November ~~$15~~30,~~235~~ as2022 ofand ~~May~~August 31, 2022, ~~compared~~the toCompany has a total additional paid-in capital - capital contribution balance of $547,~~963~~150 inand ~~Stockholders’~~$46,030, respectively. ~~Equity~~Such asincrease was due to the satisfaction of ~~August~~amount 31of $1,120 due ~~2021~~to current shareholder on November 30, 2022.

~~Three~~NOTE ~~months~~8 ~~ended~~– ~~May~~SUBSEQUENT ~~31, 2022 compared to three months May 31, 2021.~~EVENT

~~During~~In ~~three-month periods~~accordance ~~ended~~with ~~May~~ASC 31Topic 855, ~~2022~~“Subsequent Events”, which establishes general standards of accounting for and ~~2020~~disclosure weof ~~have~~events that occur after the balance sheet date but before condensed financial statements are issued, the Company has evaluated all events or transactions that occurred up to January 13, 2023, the date the financial statements were available to issue. Based upon this review, the Company did not ~~generated~~identify any ~~revenue.~~subsequent events that would have required adjustment or disclosure in the condensed financial statements.

~~During~~F-7 ~~the~~Table ~~three months ended May 31, 2022, we incurred expenses~~ of ~~$3,305 compared to $1,790 incurred during the three-month period ended May 31, 2021.~~ Contents

~~Our~~Item ~~net~~2. ~~loss~~Management’s ~~for~~Discussion ~~the~~and ~~three~~Analysis ~~months~~of ~~ended~~Financial ~~May~~Condition ~~31,~~and ~~2022~~Results ~~was~~of ~~$3,305 compared to $1,790 during the three-month period ended May 31, 2021.~~Operations

11The ~~Table~~following ofdiscussion ~~Contents~~should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this Report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this Report. Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

~~Nine~~Company ~~months ended May 31, 2022 compared to nine months May 31, 2021.~~Overview

~~During~~QLY ~~nine-month~~Biotech ~~periods~~Group ~~ended~~Corp. ~~May~~(“the 31Company” or “QLY”), ~~2022~~was incorporated in the State of Nevada on September 20, 2018. The Company was used to engaged in the tourism. The company used to organize individual and ~~2020~~group wesailing ~~have~~tours ~~not~~in ~~generated~~the ~~any~~Dominican ~~revenue~~Republic. Services and itineraries were used to be provide by our company include custom packages according to the client’s specifications. And we used to develop and offer our own sailing tours in the North part of Dominican Republic as well as third-party suppliers.

~~During~~The Company has no operations or revenue as of the ~~nine~~date ~~months~~of ~~ended~~this ~~May~~Report ~~31,~~due ~~2022,~~to wethe ~~incurred~~current ~~expenses~~director had not perform similar service. We are currently in the process of ~~$9,272~~developing ~~compared~~a business plan. Management intends to ~~$30,100~~explore ~~incurred~~and ~~during~~identify viable business opportunities within the ~~nine-month~~U.S. ~~period~~including ~~ended~~seeking ~~May~~to 31acquire a business in a reverse merger. Our ability to effectively identify, ~~2021~~develop and implement a viable plan for our business may be hindered by risks and uncertainties which are beyond our control, including without limitation, the continued negative effects of the coronavirus pandemic on the U.S. and global economies.

~~Our~~Results ~~net~~of ~~loss for the nine months ended May 31, 2022 was $9,272 compared to $30,100 during the nine-month period ended May 31, 2021.~~Operation

~~Cash~~For ~~Flows~~the ~~used~~three bymonths ~~Operating~~ended ~~Activities~~November 30, 2022 compared with the three months ended November 30, 2021

For the nine-month period ended May 31, 2022, net cash flows used in operating activities was $10,011. Net cash flows provided by operating activities was $18,816 during the nine-month period ended May 31, 2021.Revenue

~~Cash~~The ~~Flows~~Company ~~from~~generated ~~Financing~~revenue ~~Activities~~of $0 for the three months ended November 30, 2022 as compared to revenue of $0 for the three months ended November 30, 2021. The management intends to explore and identify business opportunities within the U.S., including a potential acquisition of an operating entity through a reverse merger, asset purchase or similar transaction. Our Chief Executive Officer has experience in business consulting, although no assurances can be given that he can identify and implement a viable business strategy or that any such strategy will result in profits. Our ability to effectively identify, develop and implement a viable plan for our business may be hindered by risks and uncertainties which are beyond our control, including without limitation, the continued negative effects of the coronavirus pandemic on the U.S. and global economies.

~~For the nine-month period ended May 31, 2022, net cash flows from financing activities was $5,510 received from the related party compared to $3,800 during the nine-month period ended May 31, 2021.~~2

~~Effects~~Cost of ~~COVID-19~~revenues

InCost ~~March~~of ~~2020,~~revenues ~~a novel strain~~ of ~~coronavirus~~$0 ~~(COVID-19)~~and ~~was~~$0 ~~declared~~for ~~a global pandemic by~~ the ~~World~~three ~~Health~~months ~~Organization.~~ended ~~This~~November ~~pandemic has negatively affected the U.S. and global economies~~30, ~~disrupted~~2022 ~~global supply chains~~ and ~~financial markets~~2021, ~~and led to significant travel and transportation restrictions, including mandatory closures and orders to “shelter-in-place”~~respectively.

AsOperating the pandemic continues the global tourism may continue to decline, which will continue to affect our revenue and, as a result, could adversely affect our operating results and financial condition. The Dominican government lifted the State of Emergency and allowed the resumption of commercial aviation effective July 1, however, there are still limitations regarding public activities. Social distancing protocols have been established for a variety of activities and masks are required by law in public spaces. Expenses

~~During~~Operating ~~the~~expenses ~~quarter~~of ~~ended~~$9,168 ~~May~~and 31$4,212 ~~2022,~~for the ~~Company~~three ~~was~~months ~~negatively~~ended ~~impacted~~November by30, ~~the~~2022 ~~effects~~and 2021, that were mainly consist of ~~the~~professional ~~worldwide~~fees ~~COVID-19~~such ~~pandemic,~~as ~~border~~audit ~~closer~~fees, ~~travel~~annual ~~bans~~list and ~~quarantine,~~edgar ~~and~~filing isfee ~~likely~~etc. toSuch ~~continue~~increase towas bemainly ~~adversely~~derived ~~affected~~from ~~for~~annual alist ~~significant~~and ~~period~~stock ofagency ~~time~~fee.

~~PLAN~~Net ~~OF OPERATION AND FUNDING~~Loss

WeThe ~~expect~~net ~~that~~loss ~~working~~of ~~capital~~$9,168 ~~requirements~~and ~~will~~$4,212 ~~continue~~for tothe bethree ~~funded~~months ~~through~~ended aNovember ~~combination~~30, of2022 ~~our existing funds~~ and ~~further~~2021, ~~issuances of securities~~respectively. ~~Our~~Such ~~working~~increase ~~capital~~was ~~requirements~~mainly ~~are~~derived ~~expected~~from toannual ~~increase~~list inand ~~line~~stock ~~with~~agency ~~the growth of our business~~fee.

~~Existing~~Liquidity ~~working capital, further advances~~ and ~~debt~~Capital instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) acquisition of inventory; (ii) developmental expenses associated with a start-up business; and (iii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.Resources

~~OFF-BALANCE~~As ~~SHEET~~of ~~ARRANGEMENTS~~November 30, 2022 and August 31, 2022, we had working capital deficit of $8,048 and $0, respectively. The increase in working capital deficit was reflected in the accrued liabilities and advanced from director. The Company’s net loss of $9,168 and $4,212 for the three months ended November 30, 2022 and 2021, respectively.

AsCash ofFlow ~~the~~from ~~date~~Operating of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.Activities

12Net ~~Table~~cash used in operating activities for the three months ended November 30, 2022 was $5,668 as compared to net cash used in operating activities of ~~Contents~~$4,809 for the three months ended November 30, 2021, reflecting an increase of $859 on net cash used in operating activities. Such increase was due to the Company incurred a lower net loss in current year.

~~GOING~~Cash ~~CONCERN~~Flow from Investing Activities

~~The~~Net ~~independent~~cash ~~registered~~generated ~~public~~from ~~accounting~~investing ~~firm~~activities ~~auditors’~~for ~~report~~the ~~accompanying~~three ~~our~~months ~~August~~ended ~~31,~~November 2021 financial statements contained an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared “assuming that we will continue as a going concern30,” ~~which~~2022 ~~contemplates that we will realize our assets~~ and ~~satisfy~~2021, ~~our~~was ~~liabilities~~$0 and ~~commitments~~$0, ~~in the ordinary course of business~~respectively.

~~ITEM~~Cash 3.Flow ~~QUANTITATIVE~~from ~~AND~~Financing ~~QUALITATIVE DISCLOSURES ABOUT MARKET RISK.~~Activities

AsNet acash ~~“smaller~~generated ~~reporting~~from ~~company”~~financing activities for the three months ended November 30, 2022 was $5,668 as ~~defined~~compared byto ~~Item~~net 10cash generated from financing activities of ~~Regulation S-K~~$800 for the three months ended November 30, 2021, reflecting an increase of $4,868 on net cash generated from financing activities. Such increase was mainly due to the director that paid the Company’s isoperating ~~not~~expenses ~~required~~on tobehalf ~~provide~~of ~~information~~the ~~required~~Company, bysuch ~~this~~as ~~Item~~audit fee, annual list and stock agency fee etc.

~~ITEM~~3 4.Table ~~CONTROLS~~of ~~AND PROCEDURES~~Contents

~~Disclosure~~Credit ~~Controls and Procedures~~Facilities

~~Our~~We ~~disclosure~~do ~~controls~~not ~~and~~have ~~procedures~~any ~~are~~credit ~~designed~~facilities ~~to ensure that information required to be disclosed in reports that we file~~ or ~~submit~~other ~~under~~access the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Our principal executive officer and principal financial and accounting officer have reviewed the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 Rules 13(a)-15(e) and 15(d)-15(e)) within the end of the period covered by this Quarterly Report on Form 10-Q and have concluded that the disclosure controls and procedures were effective to ~~ensure~~bank ~~that material information relating to the Company is recorded, processed, summarized, and reported in a timely manner~~credit.

~~Changes~~Contractual inObligations, ~~Internal~~Commitments ~~Controls~~and ~~over Financial Reporting~~Contingencies

~~There~~We currently have ~~been~~three nolease ~~changes~~agreement in ~~the~~place ~~Company’s~~with ~~internal~~respect ~~control~~to ~~over~~office ~~financial~~premises ~~reporting~~in ~~during~~Beijing ~~the~~and ~~nine-month~~Changsha ~~period~~China ~~covered by this report that have materially affected, or are reasonably likely~~ to ~~materially~~commence ~~affect,~~our ~~the~~business ~~Company’s internal control over financial reporting~~operations.

13Off-balance ~~Table~~Sheet ~~of Contents~~Arrangements

~~PART~~As ~~II.~~of ~~OTHER~~November ~~INFORMATION~~30, 2022, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

~~ITEM~~Item 1.3 ~~LEGAL~~Quantitative ~~PROCEEDINGS~~and Qualitative Disclosures About Market Risk.

~~Management~~As isa ~~not~~“smaller ~~aware~~reporting ofcompany” ~~any~~as ~~legal~~defined ~~proceedings contemplated~~ by ~~any~~Item ~~governmental~~10 ~~authority or any other party involving us or our properties. As~~ of ~~the~~Regulation ~~date of this Quarterly Report~~S-K, nothe ~~director,~~Company ~~officer or affiliate~~ is ~~(i)~~not arequired ~~party adverse~~ to usprovide ininformation ~~any~~required ~~legal~~by ~~proceeding,~~this ~~or (ii) has an adverse interest to us in any legal proceedings~~Item. ~~Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.~~

~~ITEM~~Item 2.4 ~~UNREGISTERED~~Controls ~~SALES~~and ~~OF EQUITY SECURITIES AND USE OF PROCEEDS~~Procedures.

~~None.~~Evaluation of Disclosure Controls and Procedures:

~~ITEM~~We 3carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of November 30, 2022. ~~DEFAULTS~~This ~~UPON~~evaluation ~~SENIOR~~was ~~SECURITIES~~carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of November 30, 2022, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

NoA ~~senior~~material ~~securities~~weakness ~~were~~is ~~issued~~a ~~and~~deficiency, ~~outstanding~~or ~~during~~a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the ~~nine-month~~company’s ~~period~~annual ~~ended~~or ~~May~~interim 31financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of November 30, 2022, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

~~ITEM~~Changes 4.in ~~MINE~~Internal ~~SAFETY~~Control ~~DISCLOSURES~~over Financial Reporting:

~~Not~~There ~~applicable~~were no changes in our internal control over financial reporting during the quarter ending November 30, 2022, that have materially affected, or are reasonably likely to materially affect, our ~~Company~~internal control over financial reporting.

~~ITEM~~4 5.Table ~~OTHER~~of ~~INFORMATION~~Contents

~~None.~~PART II — OTHER INFORMATION

~~ITEM~~Item 61. ~~EXHIBITS~~Legal Proceedings

31.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
32.1		Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

We know of no materials, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest adverse to us.

14Item ~~Table~~1A. ofRisk ~~Contents~~Factors.

~~SIGNATURES~~We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

InItem ~~accordance~~2. ~~with~~Unregistered ~~the~~Sales ~~requirements~~ of ~~the~~Equity ~~Exchange~~Securities ~~Act,~~and ~~the~~Use ~~registrant~~of ~~caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~Proceeds

	AZAR INTERNATIONAL CORP.
Dated: June 10, 2022	By:	/s/ Hilario Lopez Vargas
		Hilario Lopez Vargas,
		President and Chief Executive Officer and Chief Financial Officer

None.

15Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information.

None.

Table of Contents

ITEM 6. Exhibits

Exhibit No.		Description
31.1		Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer*
32.1		Section 1350 Certification of principal executive officer *
101.INS		XBRL Instance Document*
101.SCH		XBRL Schema Document*
101.CAL		XBRL Calculation Linkbase Document*
101.DEF		XBRL Definition Linkbase Document*
101.LAB		XBRL Label Linkbase Document*
101.PRE		XBRL Presentation Linkbase Document*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	QLY BIOTECH GROUP CORP.
	(Name of Registrant)

Date: January 13, 2023	By:	/s/ Lixue Yang
		Lixue Yang
		Chief Executive Officer, President, Secretary, Treasurer, Director

Filing Compare · QLY Biotech Group Corp.